Table 2.
Association between PDAQ‐15 scores and cognitive diagnosis in the Pacific Udall Center of Excellence in Parkinson's Disease Research
| PD‐MCI vs. No Cognitive Impairment | PDD vs. PD‐MCI | |||
|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |
| PDAQ‐P | ||||
| Age | 0.96 (0.90–1.03) | 0.247 | 1.11 (1.00–1.24) | 0.059 |
| Education | 0.97 (0.79–1.20) | 0.803 | 0.84 (0.58–1.21) | 0.346 |
| Gender | 3.78 (1.41–10.10) | 0.008 | 2.64 (0.34–20.77) | 0.356 |
| Site | 1.31 (0.72–2.38) | 0.373 | 11.34 (1.98–64.80) | 0.006 |
| Disease duration | 0.99 (0.92–1.07) | 0.874 | 1.09 (0.97–1.23) | 0.159 |
| LEDD | 0.99 (0.99–1.00) | 0.545 | 1.00 (0.99–1.00) | 0.783 |
| MDS‐UPDRS, part III | 1.00 (0.96–1.04) | 0.925 | 1.05 (0.98–1.12) | 0.183 |
| GDS | 0.87 (0.61–1.24) | 0.435 | 0.87 (0.51–1.91) | 0.970 |
| MoCA | 1.78 (1.41–2.24) | <0.001 | 2.83 (1.67–4.79) | <0.001 |
| PDAQ‐P | 1.10 (1.04–1.17) | 0.001 | 1.23 (1.10–1.37) | <0.001 |
| Total AUCa | 0.90 | 0.96 | ||
| PDAQ‐SP | ||||
| Age | 0.96 (0.90–1.03) | 0.277 | 1.10 (0.99–1.22) | 0.078 |
| Gender | 2.91 (1.15–7.36) | 0.024 | 1.80 (0.30–10.85) | 0.521 |
| Education | 0.97 (0.79–1.19) | 0.742 | 0.90 (0.65–1.25) | 0.533 |
| Site | 1.14 (0.65–2.01) | 0.642 | 3.53 (0.97–12.80) | 0.055 |
| Disease duration | 0.97 (0.90–1.04) | 0.365 | 1.09 (0.98–1.21) | 0.122 |
| LEDD | 1.00 (1.00–1.00) | 0.299 | 1.00 (0.99–1.00) | 0.334 |
| MDS‐UPDRS, part III | 0.99 (0.95–1.03) | 0.683 | 1.03 (0.97–1.09) | 0.385 |
| GDS | 0.92 (0.66–1.27) | 0.605 | 0.88 (0.47–1.65) | 0.687 |
| MoCA | 1.71 (1.38–2.13) | <0.001 | 2.47 (1.53–3.97) | <0.001 |
| PDAQ‐SP | 1.04 (0.99–1.10) | 0.120 | 1.17 (1.07–1.27) | 0.001 |
| Total AUCa | 0.88 | 0.95 | ||
AUC for the fully adjusted model.
Bold text indicates statistical significance (P < 0.05).
PDAQ‐15, Penn Parkinson's Daily Activities Questionnaire–15; PUC, Pacific Udall Center of Excellence in Parkinson's Disease Research; PD‐MCI, Parkinson's disease mild cognitive impairment; PDD, Parkinson's disease dementia; PDAQ‐P, Parkinson's Daily Activities Questionnaire–15, participant; OR, odds ratio; CI, confidence interval; LEDD, levodopa equivalent daily dose; MDS‐UPDRS, Uniform Parkinson Disease Rating Scale–Movement Disorders Society Revision; GDS, Geriatric Depression Scale; MoCA, Montreal Cognitive Assessment; AUC, area under the receiver operating characteristic curve; PDAQ‐SP, Parkinson's Daily Activities Questionnaire–15, study partner.